Erratum: Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose (The Journal of Infectious Diseases (2016) 214: 1 (16-22) DOI: 10.1093/infdis/jiv748);Antibody Levels and Protection after Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose

Journal of Infectious Diseases

Volumn 214, Issue 1, 2016, Pages 16-22

  Bruce, Michael G ^a   Bruden, Dana ^a   Hurlburt, Debby ^a   Zanis, Carolyn ^a   Thompson, Gail ^a   Rea, Lisa ^a   Toomey, Michele ^a   Townshend Bulson, Lisa ^b   Rudolph, Karen ^a   Bulkow, Lisa ^a   Spradling, Philip R ^c   Baum, Richard ^a   Hennessy, Thomas ^a   McMahon, Brian J ^a,b  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b ALASKA NATIVE TRIBAL HEALTH CONSORTIUM   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

30 years; Alaska; Alaska Native; anti HBs; antibody; cohort; hepatitis B; immunogenicity; plasma derived vaccine; US

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; RECOMBINANT HEPATITIS B VACCINE;

ADULT; ALASKA; ARTICLE; CELLULAR IMMUNITY; COHORT ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HEPATITIS B; HUMAN; IMMUNOGENICITY; LABORATORY TEST; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROLOGY; TREATMENT RESPONSE; ACTIVE IMMUNIZATION; ADOLESCENT; AGED; BLOOD; CHILD; FOLLOW UP; IMMUNOLOGY; MIDDLE AGED; PRESCHOOL CHILD; SECONDARY IMMUNIZATION; TIME FACTOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALASKA; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; IMMUNITY, ACTIVE; IMMUNIZATION, SECONDARY; MALE; MIDDLE AGED; TIME FACTORS; YOUNG ADULT;

EID: 84977067684     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiae336     Document Type: Erratum

References (25)

1. Harpaz R, McMahon BJ, Margolis HS, et al. Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program. J Infect Dis 2000; 181:413-8
2. McMahon B. Chronic hepatitis B virus infection. Med Clin North Am 2014; 98:39-54
3. Gilca V, De Serres G, Boulianne N, et al. Antibody persistence and the effect of a booster dose given 5, 10 or 15 years after vaccinating preadolescents with a recombinant hepatitis B vaccine. Vaccine 2013; 31:448-51
4. Chou R, Dana T, Bougatsos C, Blazina I, Khangura J, Zakher B. Screening for hepatitis B virus infection in adolescents and adults: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann Intern Med 2014; 161:31-45
5. FitzSimons D, McMahon B, Hendrickx G, Vorsters A, Van Damme P. Burden and prevention of viral hepatitis in the Arctic region, Copenhagen, Denmark, 22-23 March 2012. Int J Circumpolar Health 2013; 72
6. Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50:661-2
7. Keck J, Bulkow L, Raczniak G, et al. Hepatitis B virus antibody levels 7 to 9 years after booster vaccination in Alaska native persons. Clin Vaccine Immunol 2014; 21:1339-42
8. Dentinger C,McMahon B, Butler J, et al. Persistence of antibody to hepatitis B and protection from disease among Alaska natives immunized at birth. Pediat Infect Dis J 2005; 24:786-92
9. Hammitt L, Hennessy T, Fiore A, et al. Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years. Vaccine 2007; 25:6958-64
10. Gold Y, Somech R, Mandel D, Peled Y, Reif S. Decreased immune response to hepatitis B eight years after routine vaccination in Israel. Acta Paediatr 2003; 92:1158-62
11. Zanetti AR, Mariano A, Romanò L, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet (London, England) 2005; 366:1379-84
12. McMahon B, Dentinger C, Bruden D, et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis 2009; 200:1390-6
13. McMahon BJ, Schoenberg S, Bulkow L, et al. Seroprevalence of hepatitis B viral markers in 52,000 Alaska Natives. Am J Epidemiol 1993; 138:544-9
14. McMahon B, Bruden D, Petersen K, et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med 2005; 142:333-41
15. Heyward WL, Bender TR, McMahon BJ, et al. The control of hepatitis B virus infection with vaccine in Yupik Eskimos: demonstration of safety, immunogenicity, and efficacy under field conditions. Am J Epidemiol 1985; 121:914-23
16. Wainwright RB, Bulkow LR, Parkinson AJ, Zanis C, McMahon BJ. Protection provided by hepatitis B vaccine in a Yupik Eskimo population-results of a 10-year study. J Infect Dis 1997; 175:674-7
17. Ni YH, Chang MH, Wu JF, Hsu HY, Chen DS. Minimization of hepatitis B infection by a 25-year universal vaccination program. J Hepatol 2012; 57:730-5
18. Poovorawan Y, Chongsrisawat V, Theamboonlers A, Leroux Roels G, Crasta P, Hardt K. Persistence and immune memory to hepatitis B vaccine 20 years after primary vaccination of Thai infants, born to HBsAg and HBeAg positive mothers. Hum Vaccin Immunother 2012; 8:896-904
19. Mendy M, Peterson I, Hossin S, et al. Observational study of vaccine efficacy 24 years after the start of hepatitis B vaccination in two Gambian villages: no need for a booster dose. PLoS One 2013; 8:e58029
20. Coppola N, Corvino AR, De Pascalis S, et al. The long-term immunogenicity of recombinant hepatitis B virus (HBV) vaccine: contribution of universal HBV vaccination in Italy. BMC Infect Dis 2015; 15:149
21. Wang F, Shen L, Cui F, et al. The long-term efficacy, 13-23 years, of a plasma-derived hepatitis B vaccine in highly endemic areas in China. Vaccine 2015; 33:2704-9
22. Williams I, Goldstein S, Tufa J, Tauillii S, Margolis H, Mahoney F. Long term antibody response to hepatitis B vaccination beginning at birth and to subsequent booster vaccination. Pediatr Infect Dis J 2003; 22:157-63
23. Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980; 303:833-41
24. Schillie S, Murphy TV, Sawyer M, et al. CDC guidance for evaluating health-care personnel for hepatitis B virus protection and for administering postexposure management. Morb Mortal Wkly Rep Recomm Rep 2013; 62:1-19
25. Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. Morb Mortal Wkly Rep Recomm Rep 2005; 54:1-31